NEW YORK (GenomeWeb) – Veracyte announced yesterday that its Afirma Gene Expression Classifier has received positive policy coverage decisions by Health Care Service Corporation, an independent licensee of the Blue Cross Blue Shield Association, and New York's Excellus BlueCross BlueShield.

The Afirma GEC employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.